G

GSK

Develops medicines, vaccines, and consumer health

Territory Account Manager

Full-TimePosted on 10/21/2026
$145.5k - $242.5k/yr+ Annual bonus + Share-based long-term incentive
Senior
Bachelor's
San Diego, CA, USA
RemoteRemote role with domestic travel as necessary, including possible overnight travel; majority of time spent in market.
Sales & Account ManagementField Sales

About the job

Requirements
  • A BA/BS degree is required.
  • At least 5 years of pharmaceutical sales experience is required.
  • At least 3 years of specialty experience is required.
  • Ability to travel domestically as necessary, which may include overnight travel, is required; the majority of time will be spent in market.
  • A valid driver's license is required.
Responsibilities
  • Identify, target, and win new business by influencing healthcare professionals to adopt a new approach to HIV treatment.
  • Engage healthcare professionals, nurses, staff, and administrators to understand clinical, organizational, and financial challenges and opportunities within target accounts.
  • Use data analytics, business acumen, and market expertise to identify high-priority prospects.
  • Prepare and execute business plans tailored to each customer’s needs and help healthcare professionals scale their treatment models to reach more patients.
  • Coordinate and partner with cross-functional team members, including Clinical Nurse Educators and Field Reimbursement Managers, to deliver an integrated product experience to customers.
  • Maintain a portfolio-based selling mindset and close internal communication loops to provide customers with a cohesive, integrated experience.
  • Anticipate and address healthcare professional problems, needs, and requests to provide customer service.
  • Deliver and adapt execution plans to achieve performance goals and objectives using key performance indicators, scaling successful approaches, and business problem-solving.
  • Develop and foster relationships with influential customers and thought leaders.
  • Act in accordance with ViiV’s culture, expectations, and values.
  • Embrace ambiguity in a launch environment and treat setbacks as opportunities to learn and grow.
  • Escalate issues and risks when needed and speak up.
  • Understand and follow compliance and regulatory guidelines.
Desired Qualifications
  • A degree in Business, Marketing, or Life Sciences is preferred.
  • Planning and organization, analytical ability, business acumen, decision-making, and problem-solving skills are preferred.
  • Experience influencing and collaborating cross-functionally in a matrixed environment is preferred.
  • Written and oral communication skills are preferred.
  • Experience achieving sales success in complex market-access coverage situations is preferred.
  • Experience working with healthcare professionals to procure, manage, and administer cold-chain treatment products is preferred.
  • Knowledge of HIV treatment and/or prevention markets is preferred.
  • Bilingual Spanish is preferred but not required.
  • Experience partnering cross-functionally within an integrated account team model with multiple field-based team members is preferred.

About the company

GSK is a global healthcare company focused on three main areas: Pharmaceuticals, Vaccines, and Consumer Healthcare. It develops medicines, vaccines, and consumer health products to improve health outcomes worldwide. Its products address diseases in respiratory, HIV, oncology, and immuno-inflammatory areas; vaccines for influenza, shingles, and COVID-19; and over-the-counter wellness products. The company relies on substantial R&D and strategic partnerships to bring new products to market and to address health needs. Revenues come from sales of medicines, vaccines, and consumer health items, often complemented by patient support programs and collaborations with governments and biotech partners.

Company Size

10,001+

Company Stage

IPO

Headquarters

London, United Kingdom

Founded

1891

Get referred to GSK

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Luke Miels launched a £1.9 billion savings plan to fund R&D and late-stage development.
  • GSK expects more than £10 billion operating cash flow in 2026, financing acquisitions and launches.
  • Blenrep, Jideytro, and Excentia each have 2026-2027 catalysts that can lift revenue.

What critics are saying

  • Dresden’s 2027 closure cuts 641 jobs and exposes declining demand in legacy flu vaccines.
  • Camlipixant’s failure triggered a £1.3 billion impairment, showing pipeline execution remains fragile.
  • Zantac appeals and a securities case still threaten cash, disclosures, and management focus.

What makes GSK unique

  • GSK’s 62-asset pipeline spans HIV, oncology, vaccines, and respiratory with 20+ Phase III starts in 2026.
  • Jideytro, Blenrep, and Excentia create multiple launch vectors beyond Shingrix.
  • GSK’s vaccine and specialty-medicine manufacturing network supports global scale across regulated markets.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • 401(k) Retirement Plan
  • Remote Work Options
  • Flexible Work Hours
  • Paid Vacation
  • Paid Holidays
  • Hybrid Work Options
  • Wellness Program
  • Mental Health Support
  • Phone/Internet Stipend

Company News

Yahoo Finance
Oct 24th, 2026
GSK's $2.2B Zantac charge tests whether specialty medicines can carry Q3 results

GSK reports third-quarter results on October 28, with a $2.2 billion Zantac settlement charge weighing on the numbers. Consensus expects earnings per share to fall 9% year on year to $1.33, while revenue is forecast at $8.81 billion against $8.55 billion a year ago. The settlement resolves 93% of outstanding US state court cases. Investors will watch how management separates the charge from core results. Specialty Medicines grew 14% last quarter. Long-acting HIV injectables Cabenuva and Apretude rose 33% and 39%, driving 80% of ViiV's growth. The key launch to track is Exdensur, whose J-code went live on July 1. More than 50% of insured patients now have coverage, so new patient starts will be the key metric.

Pharmaceutical Executive
Oct 23rd, 2026
CSL names Deborah Waterhouse as CEO and manager director.

CSL names Deborah Waterhouse as CEO and manager director. Deborah Waterhouse is leaving ViiV Healthcare to become CEO and managing director of CSL. ViiV Healthcare has announced that Deborah Waterhouse is stepping down as chief executive officer of ViiV Healthcare and president of GSK Global Health to join CSL as chief executive officer and managing director. Lynn Baxter, currently president of GSK Europe, is set to be appointed chief executive officer of ViiV Healthcare and president of GSK Global Health, effective November 1, 2026.[1] Waterhouse's move to CSL is set to take effect February 1, 2027, following an extensive global search conducted by CSL's board. What does this mean for ViiV and CSL? Waterhouse has led ViiV Healthcare since 2017, with the company reporting sales of $10.2 billion during GSK's 2025 financial year.[1] She also served as president of GSK Global Health, a role she will relinquish alongside the ViiV CEO post. Baxter was previously leading ViiV's U.S. business for six years before moving into her current GSK Europe role, and will now oversee both ViiV Healthcare and GSK Global Health.[1] Waterhouse is expected to work with Baxter on a transition at ViiV before departing. At CSL, Gordon Naylor will continue serving as interim CEO and managing director until Waterhouse's February 2027 start date, after which he will return to the CSL board as a non-executive director.[1,2] Waterhouse will retain her base in the U.K. while spending significant time in Australia, the U.S., and CSL's other major markets and operational centers.[1,2] What is Waterhouse's track record? Waterhouse brings more than 25 years of experience managing complex global specialty pharma businesses across the U.S., U.K., continental Europe, and Australia. Before ViiV, she was the leader of GSK's U.S. vaccines business and its U.S. primary care business, along with serving as GSK's general manager for Australia and New Zealand between 2008 and 2012.[1] CSL frames her ViiV tenure as evidence she can deliver the combination of commercial growth and pipeline renewal the company says it is seeking in its next chapter. GSK leadership credits Waterhouse's tenure with both commercial and mission-driven results. "During her tenure as CEO, ViiV advanced important innovations in HIV treatment and prevention, expanded patient access to medicines, delivered sustained business growth, and strengthened its long-term strategic position," says David Redfern, chairman of the ViiV board and president of corporate development at GSK. On Baxter's appointment, he adds that her "deep experience across the biopharmaceutical industry, proven commercial leadership, and longstanding commitment to patients position her well to lead ViiV Healthcare through its next phase of growth." CSL chair Brian McNamee points to specific capabilities behind the board's decision. "She has grown a focused biopharmaceutical business and renewed the franchise at ViiV by driving the development and commercialization of the next generation of medicines to support patients," he says. "She knows the United States, she knows Australia and she knows how to build pipelines and manage partnerships." McNamee said the board's decision to appoint Waterhouse was unanimous.[2] Waterhouse addressed both moves directly. On her ViiV exit: "It has been a privilege to lead ViiV Healthcare and GSK Global Health and work alongside so many talented colleagues, partners, and advocates." She then touched on joining CSL, saying, "The foundations are strong. My job is to continue the momentum and evolve the path into reliable growth for patients and shareholders. ViiV Healthcare has reshaped the treatment and prevention landscape for people impacted by HIV. I am honored to take on this role and look forward to working with colleagues around the world to continue advancing innovation."

Yahoo Finance
Oct 23rd, 2026
GSK shares up 20.4% despite 5.2% net margin as $10.6B Nuvalent deal lifts pipeline hopes

GSK shares have risen 20.4% over the past year, including dividends, even as the company's profitability weakened. The stock now trades at £19.14, up from £16.52 at the start of the period. Revenue reached £8,409m, but net income slipped to £435m and net margin fell to 5.2%. GSK agreed to buy Nuvalent for $10.6 billion to deepen its lung cancer pipeline. It also won approvals for Jideytro, Hibsago, and the new antibiotic Utebzi. The bullish case puts fair value at £23.63, assuming 8.5% annual revenue growth and margins rising to 19.8% by 2028. The bearish case puts it at £11.2, citing cost pressure, HIV patent expiries, and pricing and legal risks. GSK plans to fund growth through a £1.9 billion cost-saving programme and site closures.

GCC Business News
Oct 21st, 2026
Mubadala Bio's IDS, GSK partner to expand medicine access in UAE.

Mubadala Bio's IDS, GSK partner to expand medicine access in UAE. Wed, 21 Oct, 2026 By Arya S Nair, Desk Reporter * Follow author on Mubadala Bio's Integrated Distribution Services (IDS) and global biopharmaceutical company GSK have signed a strategic partnership to expand access to GSK's General Medicines portfolio across the UAE, supporting national healthcare priorities and strengthening pharmaceutical supply capabilities. The agreement was signed at the Abu Dhabi Future Health Summit by Khalid Alkaf, General Manager - Pharma Logistics at Mubadala Bio, and Boyd Chongphaisal, Vice President and General Manager of GSK Gulf. Hamad Almarzooqi, Group Deputy Chief Executive Officer of Mubadala Bio, and Mohamed El Dababy, President of GSK's International Central Region, witnessed the signing. Under the agreement, IDS will manage the sales, marketing, distribution and promotion of more than 20 medicines in GSK's General Medicines portfolio across the UAE, helping expand market reach and improve access to these treatments for patients and healthcare providers nationwide. You may like. The partnership combines IDS's local market expertise and distribution capabilities with GSK's global scientific expertise and pharmaceutical portfolio to support medicine availability for patients and healthcare providers across the country. The collaboration also aims to strengthen local pharmaceutical capabilities, enhance the UAE's healthcare resilience, improve access to essential medicines, and contribute to the development of a world-class life sciences ecosystem that supports long-term healthcare innovation and sustainable growth. The agreement brings together the capabilities of a UAE-based healthcare company and a global biopharmaceutical leader to support the country's evolving healthcare needs. By combining local distribution expertise with GSK's established medicines portfolio, the partnership aims to create long-term value for patients and healthcare providers in the UAE while supporting broader healthcare objectives in the region. The alliance reflects the role of public-private and international partnerships in strengthening pharmaceutical capabilities, improving access to medicines and advancing sustainable healthcare development.

Associated Press
Oct 21st, 2026
FDA approves GSK's Hibsago, offering 19% functional cure rate for chronic hepatitis B

The US Food and Drug Administration (FDA) has approved GSK's Hibsago (bepirovirsen) for chronic hepatitis B in adults without cirrhosis. It is used alongside nucleos(t)ide analogue therapy in patients with suppressed viral DNA and surface antigen levels of 3,000 IU/ml or below. GSK says it is the first treatment of its kind to offer a potential functional cure after six months. Patients can self-administer after the first dose. In B-Well phase III trials, 19% of patients reached functional cure (233 of 1,220), against none of 614 on placebo. Standard care typically achieves less than 1% after a year. The most common adverse events were injection site redness, local pain, and a temporary rise in a liver enzyme. The label carries a boxed warning for liver flares and low platelet counts. GSK licensed the drug from Ionis. It is also approved in Japan.